Loading
IH
Inovalon Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by De Bock Peter, was filed 02 Nov 2020.
Inovalon Holdings, Inc.: what insiders have been doing
Inovalon Holdings, Inc. is a Healthcare & Pharma company based in Bowie, United States. Its directors and officers file their transactions with SEC (Form 4). Inovalon Holdings, Inc. has had no insider filing for more than a year; the last one goes back to 29 November 2021.
Our records for Inovalon Holdings, Inc. go back to 2016, with 25 purchases and 39 sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
299
Thresholds
n/a
Buy Volume
€12M
25 ops. · all time
Sell Volume
€11M
39 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
Revenue594.4M
Net income20.1M3.4% margin
Last declaration on 29 November 2021
Declarations299 total
17,073,171 shares@ US$41.0033.7% of flowClass B Common StockSEC:0001619954-21-000145:1
25,283,649 shares@ US$41.0049.9% of flowClass B Common StockSEC:0001619954-21-000145:2
7,470,435 shares@ US$41.0014.7% of flowClass B Common StockSEC:0001619954-21-000145:3
660,000 shares@ US$41.001.3% of flowClass A Common StockSEC:0001619954-21-000145:4
213,925 shares@ US$41.0076.8% of flowClass A Common StockSEC:0001619954-21-000150:2
31,515 shares@ US$41.0035.4% of flowClass B Common StockSEC:0001619954-21-000146:1
15,970 shares@ US$41.007.8% of flowClass B Common StockSEC:0001619954-21-000152:1
4,036 shares@ US$41.001.4% of flowClass A Common StockSEC:0001619954-21-000150:1
57,412 shares@ US$41.00100.0% of flowClass A Common StockSEC:0001619954-21-000146:0
5,120,000 shares0Class B Common StockSEC:0001619954-21-000145:0
50,000 shares0Class A Common StockSEC:0001619954-21-000150:0
118,907 shares@ US$41.00100.0% of flowClass A Common StockSEC:0001619954-21-000148:0
140,532 shares@ US$41.00100.0% of flowClass A Common StockSEC:0001619954-21-000151:0
153,412 shares@ US$41.00100.0% of flowClass A Common StockSEC:0001619954-21-000152:0
116,204 shares@ US$41.00100.0% of flowClass A Common StockSEC:0001619954-21-000147:0
260,093 shares@ US$41.0096.3% of flowClass A Common StockSEC:0001619954-21-000144:0
34,126 shares@ US$41.00100.0% of flowClass A Common StockSEC:0001619954-21-000149:0
4,465 shares@ US$40.991.6% of flowClass A Common StockSEC:0001619954-21-000134:0
556 shares@ US$40.770.2% of flowClass A Common StockSEC:0001619954-21-000132:0
3,643 shares@ US$40.411.3% of flowClass A Common StockSEC:0001619954-21-000123:0
216 shares@ US$34.721.2% of flowClass A Common StockSEC:0001619954-21-000121:0
1,730 shares@ US$40.540.6% of flowClass A Common StockSEC:0001619954-21-000119:0
118,907 shares0Class A Common StockSEC:0001619954-21-000107:0
9,165 sharesClass A Common StockSEC:0001619954-21-000099:0
9,165 sharesClass A Common StockSEC:0001619954-21-000097:0
25 of 299 declarations
About Inovalon Holdings, Inc.
Inovalon Holdings, Inc. (ticker: INOV) is a U.S.-based healthcare technology company listed on the NASDAQ in the United States. For French-speaking investors, Inovalon is best understood as a cloud-first healthcare data and analytics platform provider serving health plans, providers, specialty pharmacies and other participants across the healthcare value chain. Its core proposition is to help customers improve clinical quality, risk adjustment, compliance, revenue cycle performance and operational efficiency through proprietary data assets, software workflows and analytics delivered primarily through SaaS and DaaS models. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/inov-20201231.htm?utm_source=openai))
The company traces its origins to 1998 in Maryland, when it was founded as MedAssurant before evolving into Inovalon. That heritage matters: the business was built around healthcare data, measurement and population-scale analytics long before these themes became mainstream in digital health. Inovalon’s executive offices are located in Bowie, Maryland, at 4321 Collington Road, underscoring that its operating center remains firmly in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/0001619954-21-000042-index.html?utm_source=openai))
Read moreShow less
Inovalon’s main business lines are anchored in cloud-based platforms that connect data, analytics and workflow automation. The company sells solutions to payers, providers and pharmacies, with use cases spanning quality measurement, risk adjustment, claims management, revenue cycle management, pharmacy intelligence and broader population-health decision support. A key element of the investment case is the company’s ability to package these capabilities into scalable products rather than relying purely on services work. That platform orientation supports recurring revenue characteristics and makes Inovalon relevant to large enterprise healthcare customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/inov-20201231.htm?utm_source=openai))
From a competitive standpoint, Inovalon operates in a crowded but structurally attractive market that includes healthcare IT vendors, analytics specialists and data infrastructure providers. Its differentiation is based on the breadth of its data, the integration of its workflow tools, and its focus on highly regulated healthcare processes where accuracy, traceability and interoperability are critical. Management has also emphasized scale and customer breadth, with the business serving many leading U.S. health plans, providers and pharmacy organizations over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/inov-20201231.htm?utm_source=openai))
Recent developments are notable. Inovalon said it completed its multi-year transformation into a pure-play cloud-based SaaS and DaaS platform provider in early 2025, following the post-privatization restructuring of its business model. In 2025 and 2026, the company also announced or highlighted multiple AI-related and cloud partnerships, including collaborations involving AWS, Google Cloud, Oracle and Snowflake, reflecting a strategic push to expand automation, improve data accessibility and modernize healthcare operations. For investors, that means Inovalon is best viewed as a U.S. NASDAQ-listed healthcare software and data platform with a strong specialization in regulated workflows, a recurring-revenue profile, and continued optionality from AI-enabled product expansion. ([nasdaq.com](https://www.nasdaq.com/press-release/inovalon-launches-ai-solution-partnership-aws-help-health-plans-meet-new-radv-audit?utm_source=openai))
